Total Funding
18
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
188123
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.
Acquired by 
Otsuka Pharmaceuticals
Franklin P. Bymaster: Co-Founder & Chief Scientific OfficerPast Role: Eli Lilly, Senior Research Scientist
About the Company
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.
Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy
J. Barberich.
It was founded in 2009 and is headquartered in Cambridge, Massachusetts.
